leflunomide has been researched along with Psoriasis in 22 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Psoriasis: A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Leflunomide has shown promise in the treatment of psoriasis." | 9.12 | Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. ( Behrens, F; Falk, F; Kaltwasser, JP; Nash, P; Thaçi, D, 2006) |
| "To determine the safety and efficacy of leflunomide in patients with moderate to severe plaque-type psoriasis." | 9.11 | Leflunomide in the treatment of psoriasis: results of a phase II open trial. ( Barba-Gómez, JF; Guevara-Gutiérrez, E; Ornelas-Aguirre, JM; Rodríguez-Castellanos, MA; Salazar-Páramo, M; Tlacuilo-Parra, JA, 2004) |
| " We report the case of a 43-year-old man with psoriasis and psoriatic arthritis who developed AA during his treatment with adalimumab and leflunomide." | 8.88 | Alopecia areata during treatment of psoriasis with adalimumab and leflunomide: a case and review of the literature. ( Daudén, E; Gallo, E; García-Diez, A; Navarro, R; Santiago Sánchez-Mateos, D, 2012) |
| "The present study is a mechanistic validation of 'proof of concept' of effective topical delivery of leflunomide (LFD) nanoemulgel for localized efficient treatment of psoriatic lesions as well as melanoma affected skin regions." | 7.81 | Transcutaneous delivery of leflunomide nanoemulgel: Mechanistic investigation into physicomechanical characteristics, in vitro anti-psoriatic and anti-melanoma activity. ( Divate, D; Gangurde, S; Pawar, S; Pund, S, 2015) |
| "Leflunomide has shown promise in the treatment of psoriasis." | 5.12 | Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. ( Behrens, F; Falk, F; Kaltwasser, JP; Nash, P; Thaçi, D, 2006) |
| "To determine the safety and efficacy of leflunomide in patients with moderate to severe plaque-type psoriasis." | 5.11 | Leflunomide in the treatment of psoriasis: results of a phase II open trial. ( Barba-Gómez, JF; Guevara-Gutiérrez, E; Ornelas-Aguirre, JM; Rodríguez-Castellanos, MA; Salazar-Páramo, M; Tlacuilo-Parra, JA, 2004) |
| " We report the case of a 43-year-old man with psoriasis and psoriatic arthritis who developed AA during his treatment with adalimumab and leflunomide." | 4.88 | Alopecia areata during treatment of psoriasis with adalimumab and leflunomide: a case and review of the literature. ( Daudén, E; Gallo, E; García-Diez, A; Navarro, R; Santiago Sánchez-Mateos, D, 2012) |
| "A total of 17 cases of patients receiving FAEs combined with at least one other systemic therapy (methotrexate, acitretin, etanercept, cyclosporine, leflunomide and infliximab) to treat psoriasis or psoriatic arthritis were identified." | 3.81 | Systemic antipsoriatic combination therapy with fumaric acid esters for plaque-type psoriasis: report on 17 cases. ( Frambach, Y; Gerdes, S; Jacobi, A; Mössner, R; Philipp, S; Weyergraf, AJ; Wilsmann-Theis, D, 2015) |
| "The present study is a mechanistic validation of 'proof of concept' of effective topical delivery of leflunomide (LFD) nanoemulgel for localized efficient treatment of psoriatic lesions as well as melanoma affected skin regions." | 3.81 | Transcutaneous delivery of leflunomide nanoemulgel: Mechanistic investigation into physicomechanical characteristics, in vitro anti-psoriatic and anti-melanoma activity. ( Divate, D; Gangurde, S; Pawar, S; Pund, S, 2015) |
| " We administered tofacitinib combined with leflunomide to a 38-year-old female patient who presented with PsA and IgA nephropathy." | 2.82 | Tofacitinib combined with leflunomide for treatment of psoriatic arthritis with IgA nephropathy: a case report with literature review. ( Ci, X; Du, X; Li, L; Lu, X; Luo, M; Wu, L; Xue, H, 2022) |
| "Leflunomide is an oral disease-modifying antirheumatic drug administered to patients with rheumatoid and psoriatic arthritis." | 2.48 | Leflunomide in dermatology. ( Boyd, AS, 2012) |
| "Psoriatic arthritis is a comorbidity frequently associated to psoriasis." | 1.35 | [Psoriatic arthritis]. ( Bagot, M; Claudepierre, P, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (45.45) | 29.6817 |
| 2010's | 11 (50.00) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Xue, H | 1 |
| Ci, X | 1 |
| Luo, M | 1 |
| Wu, L | 1 |
| Du, X | 1 |
| Li, L | 1 |
| Lu, X | 1 |
| Gupta, A | 1 |
| Sardana, K | 1 |
| Gautam, RK | 1 |
| Kelly, JB | 1 |
| Foley, P | 1 |
| Strober, BE | 1 |
| Silva-Fernández, L | 1 |
| Pérez-Vicente, S | 1 |
| Martín-Martínez, MA | 1 |
| López-González, R | 1 |
| Wilsmann-Theis, D | 1 |
| Frambach, Y | 1 |
| Philipp, S | 1 |
| Weyergraf, AJ | 1 |
| Jacobi, A | 1 |
| Mössner, R | 2 |
| Gerdes, S | 1 |
| Pund, S | 1 |
| Pawar, S | 1 |
| Gangurde, S | 1 |
| Divate, D | 1 |
| Affleck, AG | 1 |
| Williams, H | 1 |
| Di Nuzzo, S | 1 |
| Zanni, M | 1 |
| De Panfilis, G | 1 |
| Melwani, PM | 1 |
| Peñate, Y | 1 |
| Guillermo, N | 1 |
| Soler, E | 1 |
| Hernández-Machín, B | 1 |
| Borrego, L | 1 |
| Chen, LA | 1 |
| Su, LH | 1 |
| Chang, YJ | 1 |
| Hsu, YL | 1 |
| Tsai, TH | 1 |
| Savoia, F | 1 |
| Gaddoni, G | 1 |
| Casadio, C | 1 |
| Spadola, G | 1 |
| Patrizi, A | 1 |
| Giacomini, F | 1 |
| Aldi, M | 1 |
| Boyd, AS | 1 |
| Navarro, R | 1 |
| Daudén, E | 1 |
| Gallo, E | 1 |
| Santiago Sánchez-Mateos, D | 1 |
| García-Diez, A | 1 |
| Wetter, DA | 1 |
| Tlacuilo-Parra, JA | 1 |
| Guevara-Gutiérrez, E | 1 |
| Rodríguez-Castellanos, MA | 1 |
| Ornelas-Aguirre, JM | 1 |
| Barba-Gómez, JF | 1 |
| Salazar-Páramo, M | 1 |
| Thami, GP | 1 |
| Garg, G | 1 |
| Houtman, PM | 1 |
| Nash, P | 1 |
| Thaçi, D | 1 |
| Behrens, F | 1 |
| Falk, F | 1 |
| Kaltwasser, JP | 1 |
| Claudepierre, P | 1 |
| Bagot, M | 1 |
| Reich, K | 1 |
| Hummel, KM | 1 |
| Beckmann, I | 1 |
| Neumann, C | 1 |
| Wozel, G | 1 |
| Pfeiffer, C | 1 |
6 reviews available for leflunomide and Psoriasis
| Article | Year |
|---|---|
Tofacitinib combined with leflunomide for treatment of psoriatic arthritis with IgA nephropathy: a case report with literature review.
Topics: Adult; Arthritis, Psoriatic; Female; Glomerulonephritis, IGA; Humans; Leflunomide; Piperidines; Psor | 2022 |
Current and future oral systemic therapies for psoriasis.
Topics: Acitretin; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites; Cyclosporine; Fumarates; Humans | 2015 |
New-onset psoriasis associated with etanercept therapy.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Etanercept; Humans; Immunoglobulin G; Isoxazoles | 2010 |
Leflunomide in dermatology.
Topics: Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Psoriasis; Skin Diseases | 2012 |
Alopecia areata during treatment of psoriasis with adalimumab and leflunomide: a case and review of the literature.
Topics: Adalimumab; Adult; Alopecia Areata; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Hum | 2012 |
[Leflunomide--a new drug for pharmacological immunomodulation].
Topics: Animals; Autoimmune Diseases; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Psoriasis; | 2002 |
3 trials available for leflunomide and Psoriasis
| Article | Year |
|---|---|
Leflunomide in the treatment of psoriasis: results of a phase II open trial.
Topics: Adolescent; Adult; Aged; Female; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Male; Mi | 2004 |
Leflunomide in psoriasis and psoriatic arthritis: a preliminary study.
Topics: Adjuvants, Immunologic; Adult; Aged; Arthritis, Psoriatic; Female; Humans; Isoxazoles; Leflunomide; | 2004 |
Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; | 2006 |
13 other studies available for leflunomide and Psoriasis
| Article | Year |
|---|---|
Switching to secukinumab in difficult-to-treat psoriasis recalcitrant to methotrexate, cyclosporine and leflunomide, in a tuberculosis-endemic country.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cyclosporine; Dermatologic Agents; Humans | 2019 |
Leflunomide: psoriasis, lupus.
Topics: Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Lupus Erythematosus, Cutaneous; Psoriasis | 2013 |
Variability in the prescription of non-biologic disease-modifying antirheumatic drugs for the treatment of spondyloarthritis in Spain.
Topics: Adult; Antimalarials; Antirheumatic Agents; Azathioprine; Cohort Studies; Cyclophosphamide; Cyclospo | 2015 |
Systemic antipsoriatic combination therapy with fumaric acid esters for plaque-type psoriasis: report on 17 cases.
Topics: Acitretin; Adult; Aged; Anti-Inflammatory Agents; Cyclosporine; Dermatologic Agents; Drug Therapy, C | 2015 |
Transcutaneous delivery of leflunomide nanoemulgel: Mechanistic investigation into physicomechanical characteristics, in vitro anti-psoriatic and anti-melanoma activity.
Topics: Adhesiveness; Administration, Cutaneous; Antineoplastic Agents; Cell Line, Tumor; Chemistry, Pharmac | 2015 |
Is leflunomide effective in the treatment of psoriasis in a patient who is unable to benefit from standard first- and second-line therapies and needs an affordable treatment option?
Topics: Evidence-Based Medicine; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Male; Psoriasis; | 2008 |
Cutaneous ulceration induced by leflunomide in a psoriatic patient.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Breast; Female; Humans; Isoxazoles; Leflunomide; Pso | 2009 |
Leflunomide in the treatment of palmoplantar pustulosis.
Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Ha | 2009 |
A case of eczematous and vesicular dermatitis during anti-TNFalpha therapy for rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Diagnostic Errors; Drug Eruptions; Drug Synergis | 2011 |
Palmoplantar pustulosis.
Topics: Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Middle Aged; P | 2013 |
[The practice guideline 'Photo(chemo)therapy and systemic therapy in severe chronic plaque-psoriasis'].
Topics: Dermatologic Agents; Humans; Isoxazoles; Leflunomide; Photochemotherapy; Psoriasis; Treatment Outcom | 2005 |
[Psoriatic arthritis].
Topics: Arthritis, Psoriatic; Cyclosporine; Diagnosis, Differential; Humans; Immunosuppressive Agents; Isoxa | 2008 |
Treatment of severe psoriasis and psoriatic arthritis with leflunomide.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Female; Humans; Immunosuppressive Age | 2002 |